Latest News for CSPC Pharma Gr Stock (OTC:CHJTF)

CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C, antibiotics, and a caffeine series.

CSPC PHARM GROUP LTD ORD by CSPC Pharmaceuticals Group Ltd.

CSPC Pharmaceutical Group Ltd

Analysts have been eager to weigh in on the Healthcare sector with new ratings on CSPC Pharmaceutical Group (CHJTF – Research Report), Roche Holdin...

Analysts Conflicted on These Healthcare Names: CSPC Pharmaceutical Group (OtherCHJTF), Roche Holding AG (OtherRHHVF) and Teladoc (TDOC)

Rebecca Liang, an analyst from Bernstein, maintained the Hold rating on CSPC Pharmaceutical Group (CHJTF – Research Report). The associated price t...

CSPC Pharmaceutical Group: Hold Rating Amid Mixed Financial Performance and Strategic R&D Investment

CMB International Securities analyst Jill Wu has maintained their bullish stance on CHJTF stock, giving a Buy rating on November 27. Jill Wu has gi...

CSPC Pharmaceutical Group: A Strong Buy on Solid Performance and Promising New Products

Jefferies analyst Chris Lui maintained a Buy rating on CSPC Pharmaceutical Group (CHJTF – Research Report) yesterday and set a price target of HK$8...

CSPC Pharmaceutical Group: A Strong Buy on Robust R&D and Innovative Pipeline

Jefferies Keeps Their Buy Rating on CSPC Pharmaceutical Group (CHJTF)

CSPC Pharmaceutical Group (CHJTF) Receives a Buy from Jefferies

Jefferies analyst Chris Lui maintained a Buy rating on CSPC Pharmaceutical Group (CHJTF – Research Report) on January 1 and set a price target of H...

Corbus Pharma surges after early Phase 1 data for tumor candidate

Corbus Pharma reverses gains on common stock offering

Jill Wu, an analyst from CMB International Securities, maintained the Buy rating on CSPC Pharmaceutical Group (CHJTF – Research Report). The associ...